|
GB1541435A
(en)
|
1975-02-04 |
1979-02-28 |
Searle & Co |
Immunological materials
|
|
US4036945A
(en)
|
1976-05-03 |
1977-07-19 |
The Massachusetts General Hospital |
Composition and method for determining the size and location of myocardial infarcts
|
|
US4200690A
(en)
|
1976-12-16 |
1980-04-29 |
Millipore Corporation |
Immunoassay with membrane immobilized antibody
|
|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
|
US5204095A
(en)
|
1980-04-09 |
1993-04-20 |
National Research Development Corporation |
Monoclonal antibodies against hepatitis B virus
|
|
US4359457A
(en)
|
1980-09-30 |
1982-11-16 |
Neville Jr David M |
Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
|
|
US4925922A
(en)
|
1983-02-22 |
1990-05-15 |
Xoma Corporation |
Potentiation of cytotoxic conjugates
|
|
US4916213A
(en)
|
1983-02-22 |
1990-04-10 |
Xoma Corporation |
Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5672347A
(en)
|
1984-07-05 |
1997-09-30 |
Genentech, Inc. |
Tumor necrosis factor antagonists and their use
|
|
US4824659A
(en)
|
1985-06-07 |
1989-04-25 |
Immunomedics, Inc. |
Antibody conjugates
|
|
US5525338A
(en)
|
1992-08-21 |
1996-06-11 |
Immunomedics, Inc. |
Detection and therapy of lesions with biotin/avidin conjugates
|
|
US5776093A
(en)
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
|
US4918163A
(en)
|
1985-09-27 |
1990-04-17 |
Pfizer Inc. |
Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
|
|
US5618920A
(en)
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
|
US4699784A
(en)
|
1986-02-25 |
1987-10-13 |
Center For Molecular Medicine & Immunology |
Tumoricidal methotrexate-antibody conjugate
|
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
|
US4997913A
(en)
|
1986-06-30 |
1991-03-05 |
Oncogen |
pH-sensitive immunoconjugates and methods for their use in tumor therapy
|
|
US4704692A
(en)
|
1986-09-02 |
1987-11-03 |
Ladner Robert C |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
|
CA1320905C
(en)
|
1986-11-06 |
1993-08-03 |
Joseph M. Cummins |
Treatment of immuno-resistant disease
|
|
US4932412A
(en)
|
1986-12-18 |
1990-06-12 |
Immunomedics, Inc. |
Intraoperative and endoscopic tumor detection and therapy
|
|
WO1988007553A1
(fr)
|
1987-03-26 |
1988-10-06 |
Teijin Limited |
Procede de preparation d'un complexe d'anticorps
|
|
US4981979A
(en)
|
1987-09-10 |
1991-01-01 |
Neorx Corporation |
Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
|
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Acylhydrazone derivatives of anthracycline and methods for their preparation
|
|
US5112954A
(en)
|
1988-02-26 |
1992-05-12 |
Neorx Corporation |
Method of enhancing the effect of cytotoxic agents
|
|
US4861579A
(en)
|
1988-03-17 |
1989-08-29 |
American Cyanamid Company |
Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
GB8903021D0
(en)
|
1989-02-10 |
1989-03-30 |
Celltech Ltd |
Chemical compounds
|
|
US5134075A
(en)
|
1989-02-17 |
1992-07-28 |
Oncogen Limited Partnership |
Monoclonal antibody to novel antigen associated with human tumors
|
|
US5171665A
(en)
|
1989-04-17 |
1992-12-15 |
Oncogen |
Monoclonal antibody to novel antigen associated with human tumors
|
|
JPH02283294A
(ja)
|
1989-04-24 |
1990-11-20 |
Sumitomo Chem Co Ltd |
ヒトモノクローナル抗体
|
|
SG46445A1
(en)
|
1990-01-26 |
1998-02-20 |
Immunomedics Inc |
Vaccines against cancer and infectious diseases
|
|
WO1991013974A1
(en)
|
1990-03-14 |
1991-09-19 |
The Biomembrane Institute |
Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
|
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
GB9020075D0
(en)
|
1990-09-14 |
1990-10-24 |
Filler Aaron G |
Contrast agents for magnetic resonance imaging of axonal transport
|
|
US5679640A
(en)
|
1991-02-12 |
1997-10-21 |
Cytel Corporation |
Immunosuppressant peptides
|
|
JP3105629B2
(ja)
|
1991-04-23 |
2000-11-06 |
サングスタット メディカル コーポレイション |
特異的結合ペアのメンバーの細胞活性調節接合体
|
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
EP0604580A1
(en)
|
1991-09-19 |
1994-07-06 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US6096289A
(en)
|
1992-05-06 |
2000-08-01 |
Immunomedics, Inc. |
Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
|
|
JPH08500335A
(ja)
|
1992-05-06 |
1996-01-16 |
イムノメディクス，インコーポレイテッド |
手術，血管内手技または内視鏡手技における腫瘍および病変の検出と治療
|
|
US5686072A
(en)
|
1992-06-17 |
1997-11-11 |
Board Of Regents, The University Of Texas |
Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
|
|
EP1005870B1
(en)
|
1992-11-13 |
2009-01-21 |
Biogen Idec Inc. |
Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
WO1994018955A1
(en)
|
1993-02-22 |
1994-09-01 |
Alza Corporation |
Compositions for oral delivery of active agents
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
CA2163107C
(en)
|
1993-05-17 |
2001-04-17 |
David Milton Goldenberg |
Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
|
|
US5484892A
(en)
|
1993-05-21 |
1996-01-16 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
|
|
US5565215A
(en)
|
1993-07-23 |
1996-10-15 |
Massachusettes Institute Of Technology |
Biodegradable injectable particles for imaging
|
|
US5417972A
(en)
|
1993-08-02 |
1995-05-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
|
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
|
US5824701A
(en)
|
1993-10-20 |
1998-10-20 |
Enzon, Inc. |
Taxane-based prodrugs
|
|
US5443953A
(en)
|
1993-12-08 |
1995-08-22 |
Immunomedics, Inc. |
Preparation and use of immunoconjugates
|
|
US5639725A
(en)
|
1994-04-26 |
1997-06-17 |
Children's Hospital Medical Center Corp. |
Angiostatin protein
|
|
US5686578A
(en)
|
1994-08-05 |
1997-11-11 |
Immunomedics, Inc. |
Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
|
|
US8771694B2
(en)
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
|
CA2195557C
(en)
|
1994-08-12 |
2006-10-17 |
Shui-On Leung |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
|
US5874540A
(en)
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
|
US5798554A
(en)
|
1995-02-24 |
1998-08-25 |
Consorzio Per La Ricerca Sulla Microelettronica Nel Mezzogiorno |
MOS-technology power device integrated structure and manufacturing process thereof
|
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
|
US6441025B2
(en)
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
|
EP0888125B1
(en)
|
1996-03-20 |
2004-05-26 |
Immunomedics, Inc. |
GLYCOSYLATED IgG ANTIBODIES
|
|
ATE365562T1
(de)
|
1996-05-03 |
2007-07-15 |
Immunomedics Inc |
Zielgerichtete kombinations-immuntherapie für krebs
|
|
JP2000516594A
(ja)
|
1996-07-26 |
2000-12-12 |
スミスクライン・ビーチャム・コーポレイション |
免疫細胞介在全身性疾患の改良された治療法
|
|
DE19640207A1
(de)
|
1996-09-30 |
1998-04-02 |
Bayer Ag |
Glycokonjugate von modifizierten Camptothecin-Derivaten (A- oder B-Ring-Verknüpfung)
|
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
EP0975674B1
(en)
|
1997-05-02 |
2005-08-17 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services |
Immunotoxins, comprising an onc protein, directed against malignant cells
|
|
US6368596B1
(en)
|
1997-07-08 |
2002-04-09 |
Board Of Regents, The University Of Texas System |
Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
|
|
US6165440A
(en)
|
1997-07-09 |
2000-12-26 |
Board Of Regents, The University Of Texas System |
Radiation and nanoparticles for enhancement of drug delivery in solid tumors
|
|
US6051228A
(en)
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
|
DK1071752T3
(da)
|
1998-04-21 |
2003-10-20 |
Micromet Ag |
CD19xCD3-specifikke polypeptider og anvendelsen deraf
|
|
EP1135498B1
(en)
|
1998-11-18 |
2008-01-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
|
US6201104B1
(en)
|
1998-12-04 |
2001-03-13 |
Entremed, Inc. |
Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
|
|
US6379698B1
(en)
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
|
HK1043312B
(en)
|
1999-05-07 |
2006-07-28 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
|
DE19926154A1
(de)
|
1999-06-09 |
2000-12-14 |
Ktb Tumorforschungs Gmbh |
Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
|
|
EP1194167B1
(en)
|
1999-06-09 |
2009-08-19 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target b-cells
|
|
HK1049787B
(en)
|
1999-10-01 |
2014-07-25 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US6530944B2
(en)
|
2000-02-08 |
2003-03-11 |
Rice University |
Optically-active nanoparticles for use in therapeutic and diagnostic methods
|
|
US20030133972A1
(en)
|
2000-10-11 |
2003-07-17 |
Targesome, Inc. |
Targeted multivalent macromolecules
|
|
GB0028361D0
(en)
|
2000-11-21 |
2001-01-03 |
Glaxo Group Ltd |
Method of separating extra chromosomal dna from other cellular components
|
|
GB0119665D0
(en)
|
2001-08-10 |
2001-10-03 |
Isis Innovation |
Conjugates
|
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
|
SE0104462D0
(sv)
|
2001-12-29 |
2001-12-29 |
Carlbiotech Ltd As |
Peptide purifcation (Peptidrening)
|
|
CA2476166C
(en)
|
2002-02-14 |
2011-11-15 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
CA2478047C
(en)
|
2002-03-01 |
2014-01-21 |
Immunomedics, Inc. |
Rs7 antibodies
|
|
ATE477276T1
(de)
|
2002-03-01 |
2010-08-15 |
Immunomedics Inc |
Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
|
|
FR2840532B1
(fr)
|
2002-06-11 |
2005-05-06 |
Ethypharm Sa |
Nanocapsules lipidiques furtives, procede de preparation et utilisation comme vecteur de principes(s) actif(s)
|
|
EP1572131B1
(en)
|
2002-10-08 |
2016-07-06 |
Immunomedics, Inc. |
Antibody therapy
|
|
CA2508831C
(en)
|
2002-12-13 |
2012-05-01 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
ES2572811T3
(es)
|
2004-09-09 |
2016-06-02 |
Yeda Research And Development Co., Ltd. |
Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
|
|
EP1807436B1
(en)
|
2004-10-25 |
2014-06-18 |
Intezyne Technologies Inc. |
Heterobifunctional poly(ethylene glycol) and uses thereof
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
AU2007240737B2
(en)
|
2006-04-19 |
2011-12-08 |
Crown Bioscience, Inc. |
Camptothecin-analog with a novel, "flipped" lactone-stable, E-ring and methods for making and using same
|
|
AU2009339664B2
(en)
|
2009-02-05 |
2014-12-04 |
Oncoxx Biotech S.R.L. |
Anti-Trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
|
|
ES2738700T3
(es)
|
2009-02-13 |
2020-01-24 |
Immunomedics Inc |
Inmunoconjugados con un enlace escindible intracelularmente
|
|
WO2011034954A1
(en)
|
2009-09-15 |
2011-03-24 |
Cerulean Pharma Inc. |
Treatment of cancer
|
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
|
EA201500220A1
(ru)
|
2010-05-17 |
2015-10-30 |
Ливтех, Инк. |
Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
|
|
WO2011155579A1
(ja)
|
2010-06-10 |
2011-12-15 |
北海道公立大学法人札幌医科大学 |
抗Ｔｒｏｐ－２抗体
|
|
EP3467487A1
(en)
|
2011-01-11 |
2019-04-10 |
The Governing Council Of The University Of Toronto |
Protein detection method
|
|
US9216177B2
(en)
*
|
2011-02-28 |
2015-12-22 |
Drexel University |
Small molecular inhibitors of RAD51 recombinase and methods thereof
|
|
JP5925875B2
(ja)
|
2011-04-01 |
2016-05-25 |
ワイス・エルエルシー |
抗体−薬剤コンジュゲート
|
|
CN103501825B
(zh)
|
2011-05-02 |
2017-03-15 |
免疫医疗公司 |
用于小体积施用的同种异型选择的抗体的超滤浓缩
|
|
AR088693A1
(es)
|
2011-11-11 |
2014-06-25 |
Rinat Neuroscience Corp |
Anticuerpos especificos para trop-2 y sus usos
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
ES2819573T3
(es)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
|
|
US9492566B2
(en)
*
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
AU2013360335B2
(en)
*
|
2012-12-13 |
2017-12-07 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
EP3049443A4
(en)
*
|
2013-09-27 |
2017-04-05 |
Immunomedics, Inc. |
Anti-trop-2 antibody-drug conjugates and uses thereof
|
|
JP6980980B2
(ja)
*
|
2015-06-25 |
2021-12-15 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
|
|
CN108601841A
(zh)
*
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|